The Motley Fool··Prosper Junior BakinyVertex Pharmaceuticals: Evaluating Path to Million-Dollar Returns
Vertex Pharmaceuticals needs 26% annual growth to turn $100K into $1M by 2036, but its maturing cystic fibrosis franchise and competitive pressures make this ambitious target unlikely despite solid fundamentals.
LLYVRTXbiotechcystic fibrosis